References
- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–167.
- Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E β thalassaemia in Sri Lanka. Lancet. 2005;366(9495):1467–1470.
- George E, Ann TJ. Genotype-phenotype diversity of β-thalassemia in Malaysia: treatment options and emerging therapies. Med J Malaysia. 2010;65(4):256–260.
- Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3(5):a011700.
- Giardine B, Borg J, Viennas E, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014;42(Database issue):D1063–D1069 (http://globin.cse.psu.edu/).
- Clark BE, Thein SL. Molecular diagnosis of haemoglobin disorders. Clin Lab Haematol. 2004;26(3):159–176.
- Forget BG. Molecular genetics of human hemoglobin synthesis. Ann Intern Med. 1979;91(4):605–616.
- Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26:S3–S6.
- Yu X, Kong Y, Dore LC, et al. An erythroid chaperone that facilitates folding of α-globin subunits for hemoglobin synthesis. J Clin Invest. 2007;117(7):1856–1865.
- Vasseur-Godbillon C, Hamdane D, Marden MC, et al. High-yield expression in Escherichia coli of soluble human α-hemoglobin complexed with its molecular chaperone. Protein Eng Des Sel. 2006;19(3):91–97.
- Fucharoen S, Winichagoon P. Clinical hematologic aspects of Hemoglobin E β-thalassemia. Curr Opin Hematol. 2000;7(2):106–112.
- Kihm AJ, Kong Y, Hong W, et al. An abundant erythroid protein that stabilizes free α-haemoglobin. Nature. 2002;417(6890):758–763.
- Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54–65.
- Fucharoen S, Weatherall DJ. The Hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012;2(8): a011734.
- Sangkitporn SK, Eksiri L, Sangnoi A, et al. Identification of β-globin gene mutations in Thailand using an automated fluorescence-based DNA sequencer. Int J Lab Hematol. 2009;31(5):521–527.
- Wong LP, Ong RT, Poh T, et al. Deep whole-genome sequencing of 100 Southeast Asian Malays. Am J Hum Genet. 2013;92(1):52–66.
- Sripichai O, Makarasara W, Munkongdee T, et al. A scoring system for the classification of β-thalassemia/Hb E disease severity. Am J Hematol. 2008;83(6):482–484.
- Okonechnikov K, Golosova O, Fursov M, The UGENE Team. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012;28(8):1166–1167.
- Viprakasit V, Tyan P, Rodmai S, et al. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis. 2014;9:131.
- Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018;132(17):1781–1791.
- Schwartz E. The silent carrier of β-thalassemia. N Engl J Med. 1969;281(24):1327–1333.
- Cao A, Kan YW. The prevention of thalassemia. Cold Spring Harb Perspect Med. 2013;3(2):a011775.
- Cousens NE, Gaff CL, Metcalfe SA, et al. Carrier screening for β-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18(10):1077–1083.
- Abdullah UYH, Ibrahim HM, Jassim HM, et al. Relative proteome quantification of a, b, g and d globin chains in early eluting peaks of Bio-Rad variant II® CE-HPLC of hemoglobin from healthy and β-thalassemia subjects in Malaysia. Biochem Biophys Rep. 2019;18:100635.
- Pantaleo A, Giribaldi G, Mannu F, et al. Naturally occurring anti-band 3 antibodies and red blood cell removal under physiological and pathological conditions. Autoimmun Rev. 2008;7(6):457–462.